Search Follow us

 

Xbrane’s first product offering will be Spherotide: the first generic formulation of the prostate cancer GnRH agonist triptorelin (sales $446m) made by Xbrane’s Italian subsidiary. First sales are likely to be in Iran from 2017. Bigger sales could be generated by a biosimilar of Lucentis, Xlucane, produced at a low cost using a proprietary process. Xlucane might be marketed in the US from 2021, a year after patent expiry, and from patent expiry in Europe in 2022. Lucentis sales worldwide are about $3.6bn.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs